Oct 22 (Reuters) – * HUYABIO INTERNATIONAL ANNOUNCES HBI-8000 AND NIVOLUMAB COMBINATION REDUCES THE RISK OF DISEASE PROGRESSION BY 27% IN PATIENTS WITH ADVANCED MELANOMA IN PHASE 3 TRIAL Source text:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
PHILADELPHIA -- The Eagles were sent scrambling when blood clots sidelined Jalen Hurts, likely for…
By Cassell Bryan-Low and Hyunjoo Jin Oct 22 (Reuters) - A possible merger between Elon…
By Cassell Bryan-Low and Hyunjoo Jin Oct 22 (Reuters) - A possible merger between Elon…
TAIPEI, Oct 23 (Reuters) - Almost all of Taiwan shut down on Friday ahead of…
(The opinions expressed here are those of the author, a columnist for Reuters.) By Peter…
Oct 22 (Reuters) - SpaceX is in talks with cellular infrastructure companies to secure access…